Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Corticosteroid for topical cutaneous, intranasal or inhaled application.
Indicated in the treatment of asthma, allergic rhinitis and atopic dermatitis, psoriasis and contact eczema.
Authorized use in Pediatrics from 3 years (rhinitis) and 12 years (asthma).
At the date of this last update we did not find published data on its excretion in breast milk.
Mometasone furoate is poorly absorbed after inhalation, intranasal use, and topical application (< 1%).
Its pharmacokinetic characteristics (low systemic absorption, moderately elevated molecular weight, high plasma protein binding, high pKa and large volume of distribution, make it very unlikely its excretion into breast milk in significant amounts.
Its very low oral bioavailability would make it difficult its passage to the infant’s plasma through breast milk.
Several medical societies, experts and expert consensus, consider the use of this medication to be safe and compatible with breastfeeding (Middleton 2020, National Asthma EPP 2004).
TOPICAL USE:
When used for treatment of eczema or dermatitis of the nipple, it should be preferred a lower-potency steroid together with application just after a feed in order to let the medication has disappeared before the next meal. Otherwise, wipe-out excess of cream by using a cotton gauze and avoid a continuous use for longer than one week.
Reportedly, one case of mineral-steroid toxicity occurred after a prolonged use on the nipple (De Stefano 1983).
It is advisable to avoid the application to the nipple of creams, gels and other topical products containing paraffin (mineral oil) so that the infant does not absorb them (Concin 2008, Noti 2003).